VBI Vaccines, Inc. Banner Image

VBI Vaccines, Inc.

  • Ticker VBIV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
VBI Vaccines, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel and recently completedMore its Phase 3 program in the U.S., Europe, and Canada; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.
4.7 / 5.0 (162)

VBI Vaccines, Inc. reports have an aggregate usefulness score of 4.7 based on 162 reviews.

VBI Vaccines, Inc.

Most Recent Annual Report

VBI Vaccines, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

VBI Vaccines, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!